These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 8730977

  • 1. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS, Phillips AC, Rieutord A, Shenfield GM.
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [Abstract] [Full Text] [Related]

  • 2. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK, Brøsen K, Hansen MG, Gram LF.
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [Abstract] [Full Text] [Related]

  • 3. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE, Relling MV.
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [Abstract] [Full Text] [Related]

  • 4. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z, Fiset C, Gilbert M, Moerike K, Bélanger PM, Turgeon J.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
    Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M.
    Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.
    Gross AS, Mikus G, Fischer C, Eichelbaum M.
    Eur J Clin Pharmacol; 1991 May; 40(2):155-62. PubMed ID: 1906003
    [Abstract] [Full Text] [Related]

  • 12. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA.
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y, Slanar O, Krausz KW, Chen C, Slavík J, McPhail KL, Zabriskie TM, Perlík F, Gonzalez FJ, Idle JR.
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [Abstract] [Full Text] [Related]

  • 15. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
    Anthony LB, Boeve TJ, Hande KR.
    Cancer Chemother Pharmacol; 1995 Sep; 36(2):125-8. PubMed ID: 7767948
    [Abstract] [Full Text] [Related]

  • 16. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M.
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y.
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [Abstract] [Full Text] [Related]

  • 20. Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.
    Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C.
    Drug Metab Dispos; 2003 Jan; 31(1):76-87. PubMed ID: 12485956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.